Literature DB >> 15066146

Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease.

Takao Yasuhara1, Tetsuro Shingo, Kazuki Kobayashi, Akira Takeuchi, Akimasa Yano, Kenichiro Muraoka, Toshihiro Matsui, Yasuyuki Miyoshi, Hirofumi Hamada, Isao Date.   

Abstract

Vascular endothelial growth factor (VEGF) has previously been shown to display neuroprotective effects following ischemia, suggesting that VEGF may potentially be applied as a neuroprotective agent for the treatment of other neurological diseases. In this study, we investigated the neuroprotective capacity of VEGF in a model of Parkinson's disease. VEGF was found to be neuroprotective against cell death of primary E14 murine ventral mesencephalic neurons induced by 6-hydroxydopamine (6-OHDA) treatment in vitro. Further, rats receiving a continuous infusion of VEGF into the striatum via encapsulated hVEGF-secreting cells (baby hamster kidney-VEGF) displayed a significant decrease in amphetamine-induced rotational behavior and a significant preservation of tyrosine hydroxylase-positive neurons and fibers compared with control animals. VEGF likely functions via direct mechanisms by signaling through the neuropilin receptor expressed upon dopaminergic neurons in response to 6-OHDA treatment. Further, VEGF is likely to promote neuroprotection indirectly by activating the proliferation of glia and by promoting angiogenesis. Our results support a potential neuroprotective role for VEGF in the treatment of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15066146     DOI: 10.1111/j.1460-9568.2004.03254.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  65 in total

1.  Expression of vascular endothelial growth factor receptor-3 mRNA in the developing rat cerebellum.

Authors:  Yun Hou; Jeong-Sun Choi; Yoo-Jin Shin; Jung-Ho Cha; Jae-Youn Choi; Myung-Hoon Chun; Mun-Yong Lee
Journal:  Cell Mol Neurobiol       Date:  2010-11-12       Impact factor: 5.046

2.  Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian.

Authors:  C Barcia; V Bautista; A Sánchez-Bahillo; E Fernández-Villalba; B Faucheux; M Poza y Poza; A Fernandez Barreiro; E C Hirsch; M-T Herrero
Journal:  J Neural Transm (Vienna)       Date:  2005-01-24       Impact factor: 3.575

3.  Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease--Effects of Nanoencapsulated Neurotrophic Factors Administration.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; A Garcia-Blanco; E Herrán; A Aristieta; M Igartua; L Ugedo; J L Pedraz; R M Hernández; J V Lafuente
Journal:  Mol Neurobiol       Date:  2015-06-04       Impact factor: 5.590

4.  High-resolution whole-genome association study of Parkinson disease.

Authors:  Demetrius M Maraganore; Mariza de Andrade; Timothy G Lesnick; Kari J Strain; Matthew J Farrer; Walter A Rocca; P V Krishna Pant; Kelly A Frazer; David R Cox; Dennis G Ballinger
Journal:  Am J Hum Genet       Date:  2005-09-09       Impact factor: 11.025

Review 5.  The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson's Disease.

Authors:  Torsten Falk; Robert T Gonzalez; Scott J Sherman
Journal:  Int J Mol Sci       Date:  2010-08-05       Impact factor: 5.923

6.  Catalpol increases brain angiogenesis and up-regulates VEGF and EPO in the rat after permanent middle cerebral artery occlusion.

Authors:  Hui-Feng Zhu; Dong Wan; Yong Luo; Jia-Li Zhou; Li Chen; Xiao-Yu Xu
Journal:  Int J Biol Sci       Date:  2010-08-20       Impact factor: 6.580

7.  Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.

Authors:  X Yue; D J Hariri; B Caballero; S Zhang; M J Bartlett; O Kaut; D W Mount; U Wüllner; S J Sherman; T Falk
Journal:  Neuroscience       Date:  2013-11-27       Impact factor: 3.590

Review 8.  VEGF ligands and receptors: implications in neurodevelopment and neurodegeneration.

Authors:  Peter Carmeliet; Carmen Ruiz de Almodovar; Ruiz de Almodovar Carmen
Journal:  Cell Mol Life Sci       Date:  2013-03-12       Impact factor: 9.261

9.  Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease.

Authors:  Torsten Falk; Shiling Zhang; Scott J Sherman
Journal:  Mol Neurodegener       Date:  2009-12-10       Impact factor: 14.195

10.  Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke.

Authors:  Noriyuki Matsukawa; Takao Yasuhara; Koichi Hara; Lin Xu; Mina Maki; Guolong Yu; Yuji Kaneko; Kosei Ojika; David C Hess; Cesar V Borlongan
Journal:  BMC Neurosci       Date:  2009-10-06       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.